| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Eric Lefebvre last filed a Form 4 in January 2025, as Chief Medical Officer at PLRX. From December 2020 to January 2025, the filings on record show 0 open-market purchases and 12 sales. Eric Lefebvre's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Eric Lefebvre's trades have earned a strong insider score of 82/100 across 11 rated trades. Over a 12-month horizon, all 11 of those trades were profitable, with an average 12-month return of +50.4%.
At the last filing, the largest reported position was 240,224 shares of PLRX. The PLRX filings lean toward selling, a net 198,545 shares.
Shares as reported in the last Form 4 for each company; the most recent is from January 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2021 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell | 12,500 | $39.41 | $492,677.75 | -7.7% | -23.7% | -79.5% | |
| Dec 18, 2020 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell | 12,500 | $26.54 | $331,751.72 | -7.2% | - | - |